Oncology and Hematologic Malignancies
Novartis Pharma AG funds a broad oncology portfolio spanning solid tumours and blood cancers, with particular interest in breast cancer, prostate cancer, lung cancer, colorectal cancer, ovarian cancer, melanoma, and glioblastoma. Its studies also extend across lymphoma, leukemia, multiple myeloma, and other advanced malignancies.
- Advanced solid tumours
- Breast and prostate cancers
- Lymphoma and leukemia
- Glioblastoma and melanoma
The trial portfolio includes cancers defined by molecular features such as KRAS G12C, PIK3CA, EGFR, BRAF, IDH1, and PSMA expression, alongside radioligand and immunotherapy-related research in metastatic disease.
Immunology, Inflammation, and Autoimmune Disease
The sponsor supports research in immune-mediated disorders including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Sjögren’s syndrome, and systemic sclerosis. It also studies immune thrombocytopenia, warm autoimmune hemolytic anemia, and vasculitis.
- Systemic autoimmune diseases
- Inflammatory arthritides
- Immune cytopenias
- Autoinflammatory syndromes
Additional work covers hidradenitis suppurativa, chronic spontaneous urticaria, atopic dermatitis, food allergy, and autoinflammatory diseases linked to rare genetic immune dysregulation.
Cardiovascular and Metabolic Disorders
Novartis invests in studies of atherosclerotic cardiovascular disease, acute coronary syndrome, atrial fibrillation, heart failure, calcific aortic valve stenosis, and cardiovascular risk reduction. The portfolio also includes lipid-related conditions such as elevated lipoprotein(a), familial hypercholesterolemia, and hypercholesterolemia.
- Coronary and structural heart disease
- Arrhythmia and heart failure
- Lipid disorders
- Atherosclerotic risk reduction
Related research includes pulmonary arterial hypertension, non-obstructive coronary artery disease, and inflammatory cardiovascular mechanisms involving CHIP.
Nephrology, Complement-Mediated, and Renal Disease
The sponsor maintains active interest in chronic kidney disease, acute kidney injury, IgA nephropathy, atypical hemolytic uremic syndrome, complement 3 glomerulopathy, and idiopathic immune-complex membranoproliferative glomerulonephritis. Its renal portfolio also includes lupus nephritis and sepsis-associated acute kidney injury.
- Glomerular disease
- Complement-mediated disorders
- Kidney injury and chronic kidney disease
- Immune-mediated renal disease
Research extends to paroxysmal nocturnal hemoglobinuria and other complement-driven conditions that intersect with renal and hematologic complications.
Neurology, Ophthalmology, and Rare Genetic Disease
The sponsor funds clinical research in multiple sclerosis, myasthenia gravis, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and schizophrenia. It also studies spinal muscular atrophy, progressive supranuclear palsy, refractory seizures, and Alzheimer’s disease.
- Demyelinating disease
- Neuromuscular disorders
- Neurodegenerative disease
- Rare inherited conditions
Additional research includes age-related macular degeneration, retinitis pigmentosa, PIK3CA-related overgrowth spectrum, lymphatic malformations, and other rare disorders with genetic and developmental origins.
